L-Glutamic acid

Pricing Availability   Qty
Description: Endogenous, non-selective glutamate receptor agonist
Chemical Name: (S)-1-Aminopropane-1,3-dicarboxylic acid
Datasheet
Citations (9)
Reviews (3)
Literature (2)

Biological Activity for L-Glutamic acid

L-Glutamic acid is a the predominant excitatory transmitter in the mammalian central nervous system. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors.

MNI-caged-L-glutamate (Cat. No. 1490) also available.

Technical Data for L-Glutamic acid

M. Wt 147.13
Formula C5H9NO4
Storage Store at RT
CAS Number 56-86-0
PubChem ID 33032
InChI Key WHUUTDBJXJRKMK-VKHMYHEASA-N
Smiles [H][C@@](CCC(O)=O)(N)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for L-Glutamic acid

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
1eq. NaOH 100

Preparing Stock Solutions for L-Glutamic acid

The following data is based on the product molecular weight 147.13. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 6.8 mL 33.98 mL 67.97 mL
5 mM 1.36 mL 6.8 mL 13.59 mL
10 mM 0.68 mL 3.4 mL 6.8 mL
50 mM 0.14 mL 0.68 mL 1.36 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for L-Glutamic acid

References for L-Glutamic acid

References are publications that support the biological activity of the product.

Monaghan et al (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu.Rev.Pharmacol.Toxicol. 29 365 PMID: 2543272

Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165 PMID: 6112965

Yang and Stockwell et al (2016) Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 26 165 PMID: 26653790


If you know of a relevant reference for L-Glutamic acid, please let us know.

View Related Products by Product Action

View all Non-selective Metabotropic Glutamate Agonists

Keywords: L-Glutamic acid, L-Glutamic acid supplier, Endogenous, non-selective, agonists, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, Non-selective, mGlu, Ferroptosis, Amino, Acids, 0218, Tocris Bioscience

9 Citations for L-Glutamic acid

Citations are publications that use Tocris products. Selected citations for L-Glutamic acid include:

Schitine et al (2015) Functional plasticity of GAT-3 in avian Müller cells is regulated by neurons via a glutamatergic input. J Neurosci 82 42 PMID: 25700791

Falcucci et al (2019) Novel positive allosteric modulators of glutamate transport have neuroprotective properties in an in vitro excitotoxic model. ACS Chem Neurosci 10 3437 PMID: 31257852

Owaisat et al (2012) In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett 525 12 PMID: 22877698

Tallarida et al (2012) Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay. Amino Acids 42 2521 PMID: 21850438


Do you know of a great paper that uses L-Glutamic acid from Tocris? Please let us know.

Reviews for L-Glutamic acid

Average Rating: 4.7 (Based on 3 Reviews.)

5 Star
67%
4 Star
33%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used L-Glutamic acid?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Action of felbamate and beta-alanine on NMDA receptors.
By Anonymous on 06/21/2023
Assay Type: Ex Vivo
Species: Mouse
Cell Line/Tissue: Cerebellum

Glutamic acid (10 mM) + glycine (10 mM) were used to activate NMDA receptors in outside-out membrane patch and then test action of beta-alanine and felbamate on glycine binding site. As expected, activation of NMDARs was fully legible.

PMID: 36038575
review image

Neuron glia culture.
By Anonymous on 07/12/2020
Assay Type: In Vitro
Species: Mouse
Cell Line/Tissue: Mixed neuron-glia

L-glutamate (10 or 100μM)

Incubate for 24h

PMID: 31257852
review image

works good.
By Anonymous on 04/04/2020
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: Sprague-Dawley rats primary neuronal

10 μM L-Glutamic acid for 2 hours

PMID: 31291571 Reference
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.